Novo Nordisk's Technical Rebound Faces Its Toughest Test: The Q2 Earnings Report

Shares climb above 200-day moving average, but pricing concessions and mixed clinical data test Novo Nordisk's recovery ahead of Q2 results.

Novo Nordisk's shares have clawed back 13% over the past month, pushing the stock back above its 200-day moving average — a technical milestone that chartists view as a potential turning point. Yet beneath that surface-level recovery, the Danish pharmaceutical giant is wrestling with a formidable set of challenges: aggressive US pricing concessions, pipeline setbacks, and the looming question of whether volume growth can outrun margin compression. The answer may come on August 5, when Novo Nordisk reports second-quarter results — the first to show the full financial impact of its expanded Medicare and direct-to-consumer pricing initiatives.

The company has been leaning heavily on share buybacks to signal confidence. Between July 6 and July 10, Novo Nordisk repurchased 975,000 B-shares for a total of 2.73 billion Danish kroner, bringing the program's cumulative tally since February 4 to nearly 24 million shares worth 6.53 billion kroner. The buyback, which runs until February 1, 2027, has a ceiling of 15 billion kroner, with roughly 11.2 billion currently allocated to the current tranche. The treasury now holds 41.2 million own shares, representing about 0.9% of the share capital.

The Pricing Revolution That Could Reshape Margins

The stock's chart-based momentum coincides with a radical restructuring of Novo Nordisk's US pricing model — a shift that began in earnest at the start of 2026. By joining programs such as the "TrumpRx" direct-sales channel and a Medicare pilot, the company has slashed the monthly cash price for its GLP-1 drugs Wegovy and Ozempic to around $350 in certain distribution channels, down from levels that often topped $1,000. Additionally, a Medicare cost-sharing arrangement introduced in July caps patient out-of-pocket expenses at $50 per month. Management has previously indicated these initiatives could shave global revenue in the low single digits for 2026, but the full picture will only emerge when second-quarter numbers are published.

The critical metric for investors is whether the surge in patient access — driven by the more affordable pricing and the success of the oral Wegovy pill, which captured roughly a third of all Wegovy prescriptions by May 2026 — can offset the per-unit revenue loss. Goldman Sachs sees peak sales for the pill exceeding 40 billion kroner. Over 20,000 prescriptions were written in the second week after its US launch on January 5, and the trajectory has only steepened since.

Pipeline Progress and Setbacks in Equal Measure

On the clinical front, the narrative is mixed. The combined therapy CagriSema posted a 23% weight loss after 84 weeks in a Phase 3 study — a strong figure, but one that fell short of the 25% achieved by Eli Lilly's Zepbound. More troubling, CagriSema failed to demonstrate non-inferiority against Lilly's high-dose tirzepatide in the REDEFINE-4 trial earlier in the year. CEO Mike Doustdar has countered by calling CagriSema a "fantastic medicine" and pointing to the planned REDEFINE-11 study investigating higher doses. Separate Phase 3 data from the REIMAGINE program, released in June, showed that CagriSema delivered superior weight reduction and blood-sugar control in type 2 diabetes patients compared with existing therapies. Meanwhile, the company presented Phase 2 results for the next-generation molecule Zenagamtide (also known as amycretin) at the ADA 2026 Scientific Sessions, with Phase 3 development expected to start in the second half of the year.

Offsetting those bright spots are reminders of the risks inherent in drug development. Last November, Novo Nordisk halted two Phase 3 Alzheimer's trials of semaglutide after more than 3,500 patients showed no delay in disease progression — a failure that wiped out 9% of the stock in a single session and scuppered a potential revenue stream Morgan Stanley had estimated at over $4 billion annually.

Capacity Crunch and Competitive Pressure

The rapid uptake of oral Wegovy has brought manufacturing capacity into sharp focus. Management is reportedly weighing additional production investments, including contract manufacturing in China, though concrete details are not expected until the September capital markets day. The need for speed is amplified by intensifying competition: Eli Lilly launched its own oral GLP-1 drug Foundayo, and recently presented Phase 3 data for retatrutide showing weight loss comparable to bariatric surgery — a signal that the obesity-treatment market is becoming increasingly contested.

The Technical Picture Now

At Tuesday's close, Novo Nordisk shares stood at €42.91 in Frankfurt, having risen 0.30% on the week. The stock is 5.84% above its 200-day moving average (€40.54) and 8.05% above the 50-day average (€39.71). The relative strength index sits at 62.1, comfortably in positive territory but short of the overbought threshold of 70 — suggesting room for further upside if fundamentals cooperate. Still, on a 12-month basis the stock remains down 26.2%, and the distance to its 52-week high of €60.95 is nearly 30%. The dividend yield of 3.5%, supported by a payout ratio of 40%, provides a floor for income-focused investors even as the growth narrative wobbles.

What to Watch Next

The bull case hinges on three pillars: a strong August earnings report demonstrating that volume growth is offsetting price erosion, continued pipeline momentum from CagriSema and Zenagamtide, and the chart-supported view that the stock has bottomed. The bear case worries that the full margin impact of the US pricing overhaul has yet to show up in reported numbers, that competitive threats from Lilly and others will only intensify, and that the rally is merely a pause before another leg lower.

For now, the technicals favour the bulls as long as the share price holds above the 200-day average. A decisive break below that level would put the 50-day line at €39.71 in focus. The August 5 earnings call will be the first true test of whether this rebound has real legs — or is just a summer breather in a longer correction.